Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 90/100

Failure Rate

33.3%

3 terminated/withdrawn out of 9 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 6 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2

5(55.6%)

Phase 1

4(44.4%)

9Total

Phase 2(5)

Phase 1(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT01601340Phase 2Terminated

Effects of HQK-1001 in Patients With Sickle Cell Disease

Role: lead

NCT01322269Phase 2Completed

A Study of HQK-1001 in Patients With Sickle Cell Disease

Role: lead

NCT01642758Phase 2Completed

Trial of HQK-1001 in Beta Thalassemia Intermedia in Lebanon

Role: collaborator

NCT00842088Phase 1Completed

Phase 1/2 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HQK-1001 Administered Daily in Patients With Sickle Cell Disease

Role: lead

NCT00917826Phase 2Terminated

Study of Arginine Butyrate and Ganciclovir/Valganciclovir in EBV(+) Lymphoid Malignancies

Role: lead

NCT00992732Phase 2Terminated

Study of HQK-1004 and Valganciclovir to Treat Epstein-Barr Virus (EBV) - Positive Lymphoid Malignancies or Lymphoproliferative Disorders

Role: lead

NCT00790127Phase 1Completed

Phase 1/2 Study of HQK-1001 in Patients With Beta Thalassemia

Role: lead

NCT00717262Phase 1Completed

Phase 1 Placebo Controlled Study of the Safety, Activity and Pharmacokinetics of HQK-1001 in Healthy Subjects

Role: lead

NCT00614016Phase 1Completed

A Phase 1, Single-Dose Safety and Pharmacokinetic Study of Sodium ST20 in Healthy Volunteers

Role: lead

All 9 trials loaded